Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score ≥ 24 points - Data from the ropinirole clinical trial programme

Current Medical Research and Opinion

Volumn 22, Issue 10, 2006, Pages 1867-1877

  Giorgi, Luigi ^a,b   Ritchie, Sally Y ^a   Kirsch, Jeffrey M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Neurosciences MDC   (United Kingdom)

Author keywords

Clinical research trial; IRLS; Restless legs syndrome; Ropinirole

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PLACEBO; ROPINIROLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HEALTH SURVEY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SCORING SYSTEM; SHORT FORM 36; SOMNOLENCE; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; AGED; DOPAMINE AGONISTS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RESTLESS LEGS SYNDROME; TREATMENT OUTCOME;

EID: 33750529946     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X132442     Document Type: Article

References (32)

1. GlaxoSmithKline Clinical Trial Register. Available from http://ctr.gsk.co.uk/Summary/ropinirole/studylist.asp [Last accessed 22 May 2006]
2. Allen R, Picchietti D, Hening W, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19
3. Allen RP, Walters A, Montplaisir J, et al. Restless legs syndrome prevalence and impact. Arch Intern Med 2005;165:1286-92
4. Tison F, Crochard A, Leger D, et al. Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology 2005;65:239-46
5. Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS) epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004;5:237-46
6. Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004;26:925-35
7. Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997;12:61-5
8. Comella CL. Restless legs syndrome: treatment with dopaminergic agents. Neurology 2002;58(Suppl 1):S87-92
9. Michaud M, Soucy JP, Chabli A, et al. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002;249:164-70
10. Ruottinen HM, Partinen M, Hublin C, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000;54:502-4
11. Fulda S, Wetter TC. Dopamine agonists for the treatment of restless legs syndrome. Expert Opin Pharmacother 2005;6:2655-66
12. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-13
13. Schapira A. Restless legs syndrome: an update on treatment options. Drugs 2004;64:149-58
14. Bogan RK, Fry JM, Schmidt MH, et al. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo controlled clinical trial. Mayo Clinic Proceedings 2006;81:17-27
15. Montplaisir J, Karrasch J, Haan J, et al. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized, controlled trial. Mov Disord 2006; Jul 27 [Epub ahead of print]
16. Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep 2003;26:819-21
17. Stiasny-Kolster K, Benes H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 2004;63:2272-9
18. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004;5:9-14
19. Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004;27:907-14
20. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92-7
21. Walters AS, Ondo WG, Dreykluft T, et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19:1414-23
22. Garcia-Borreguero D, Lee D, Ball E. Ropinirole is well tolerated and effective for the long-term treatment of RLS. Neurology 2005;64(Suppl 5):P01.046, A42
23. Walters AS. The International Restless Legs Syndrome Study Group. Toward a better definition of the restless legs syndrome. Mov Disord 1995;10:634-42
24. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-32
25. Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health: US Dept. of Health, Education, and Welfare publication (ADM) 76-338. 1976, pp.218-22
26. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE Jr, editors. Measuring functioning and well-being. The Medical Outcomes Study approach. Durham and London: Duke University Press, 1992, pp.235-59
27. Hays RD, Martin SA, Sesti AM, et al. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med 2005;6:41-4
28. Abetz L, Arbuckle R, Allen R, et al. The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population. Health Qual Life Outcomes 2005;3:79
29. Abetz L, Vallow SM, Kirsch J, et al. Validation of the Restless Legs Syndrome Quality of Life questionnaire. Value Health 2005;8:157-67
30. Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey - manual and interpretation guide. Boston: The Health Institute, New England Medical Center, 1993
31. Dreykluft T, Garcia-Borreguero D, Lee D. Long-term safety and efficacy of ropinirole in moderate-to-severe RLS: results of two 52-week, open-label studies. Eur J Neurol 2005;12(suppl 2):96; P1244
32. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999;15:141-55